

## Patent on technology platform SBG granted Biotec Pharmacon in the US

**(Tromsø 4. May 2017) Biotec Pharmacon ASA (OSE: BIOTEC) has been granted patent in the US for the technology platform of gel forming Soluble Beta-Glucan (SBG).**

The granted patent US 9,623,043 title of invention: Glucan. The claims cover the method for producing a gel forming SBG and the product obtainable by this method as well as the medical use of the glucan gel. The patent is valid to 2031

“We are very pleased with this patent as it secures our intellectual property in the important US market for the technology platform of Woulgan. It will be important in the market development not least in the partner discussions as it gives a potential partner security that any investments made is being protected”, says Svein Lien, CEO, Biotec Pharmacon ASA

### **For additional information,**

Svein Lien, CEO, +47 922 89 323, [svein.lien@biotec.no](mailto:svein.lien@biotec.no)

### **About Biotec Pharmacon ASA:**

*Biotec Pharmacon ASA is the parent company of Biotec BetaGlucans AS and ArcticZymes AS. Biotec BetaGlucans develops, manufactures and markets novel immunomodulating products, including Woulgan®, a premium priced product in the advanced wound care market. ArcticZymes develops, produces and markets enzymes of marine origin used in molecular DNA technologies and diagnostics, representing growth markets where rapid technological developments are creating a strong demand for new and improved enzymes.*